Preprints.org · 2023 · 10 citations · 33 references
MedicineCancer BiologyOncologyImmunotherapyNeuro-oncologyTumor MicroenvironmentCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyGlioblastomaImmune Checkpoint InhibitorsTumor Immune MicroenvironmentGlioblastoma Immune EvasionGlioblastoma ImmunotherapyGlioblastoma Tumor MicroenvironmentImmune Checkpoint Inhibitor TherapyImmunosuppressive MicroenvironmentPrimary Central Nervous System TumorsTumor Microenvironment ResistanceTumor Microenvironment-mediated Resistance
Gliomas are aggressive, primary central nervous system tumours arising from glial cells. Glioblastomas are the most malignant. They are known for their poor prognosis or median overall survival. Current standard of care is overwhelmed by the heterogeneous, immunosuppressive tumour microenvironment promoting immune evasion and tumour proliferation. The advent of immunotherapy with its various modalities – immune checkpoint inhibitors, cancer vaccines, oncolytic viruses, chimeric antigen receptor T cells and NK cells have shown promise. Clinical trials incorporating combination therapies of the above have overcome the microenvironment resistance and yielded survival and prognostic benefit. Rolling these new therapies out in the real-world scenario in a low cost, high throughput manner is the unmet need of the hour. These will bring practice changing implications to the glioma treatment landscape. In this review article, we focus on describing the hallmarks of the glioma microenvironment and its interplay with the different emerging modalities of immunotherapy.
33
Roger Stupp, Monika E. Hegi, Warren Mason et al. · The Lancet Oncology · 2009 · 7.8K citations
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text
Medicine, Hematology, Oncology +16
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner et al. · New England Journal of Medicine · 2018 · 5.6K citations · Full text
Medicine, Hematology, Oncology +17
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu, David Marín, Pinaki P. Banerjee et al. · New England Journal of Medicine · 2020 · 2.1K citations · Full text
Life Sciences, Immunology, Oncology +17
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Christine E. Brown, Darya Alizadeh, Renate Starr et al. · New England Journal of Medicine · 2016 · 1.8K citations · Full text
Medicine, Immunology, Oncology +17